Real‐World Evaluation Screening Study and Registry of Dyskinesia in Patients Taking Antipsychotic Agents

Trial Profile

Real‐World Evaluation Screening Study and Registry of Dyskinesia in Patients Taking Antipsychotic Agents

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 24 Nov 2017

At a glance

  • Drugs Valbenazine (Primary)
  • Indications Drug-induced dyskinesia
  • Focus Therapeutic Use
  • Acronyms RE-Kinect
  • Sponsors Neurocrine Biosciences
  • Most Recent Events

    • 07 Nov 2017 According to a Neurocrine Biosciences media release, data will be presented at the 2017 Neuroscience Education Institute Congress.
    • 19 Sep 2017 New trial record
    • 15 Sep 2017 According to a Neurocrine Biosciences media release, data will be presented at the 2017 Annual Psych Congress annual meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top